BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Apitope Grows Operations with Move to St Brandon's House, Bristol, UK


10/1/2010 12:14:21 PM

Bristol, England / Hasselt, Belgium – 01 October 2010: Apitope International N.V., the biopharmaceutical company developing peptide therapies for autoimmune diseases, announced today that it has relocated its UK subsidiary HQ to larger premises at St Brandon’s House in Bristol, England as a result of significant growth in Apitope’s business and staff. St Brandon’s House is a distinguished Grade II listed Georgian building ideally located in the heart of Bristol's business district but remaining close to the university.

Apitope was spun out of Bristol University in 2002, and since then has raised significant investment from specialist life sciences investors. In January 2009, Apitope signed an agreement with Merck Serono for the development and commercialisation of its lead product ATX-MS-1467. ATX-MS-1467 is a potentially disease-modifying therapy for the treatment of MS.

Keith Martin, CEO of Apitope said:

“Apitope has enjoyed a number of successful years in the Set Squared Centre at University Gate East and the larger premises at St Brandon’s House allow us to embark on the next phase of growth as we expand our management team, staff and business activities.”

For further information:

Apitope International N.V. Dr. Keith Martin, CEO +44 (0)117 920 0062 keith.martin@apitope.com

Capital MS&L Limited Mary Clark, Head of Life Sciences +44 20 7307 5330 mary.clark@capitalmsl.com

About Apitope

Apitope is a European biotechnology company focusing on the discovery and development of revolutionary disease modifying therapies for treating autoimmune and allergic diseases, including multiple sclerosis, and Graves’ disease. It has headquarters in Hasselt, Belgium and a subsidiary in Bristol, UK.

The Company is developing potential therapies to selectively treat the underlying cause of a range of autoimmunediseases rather than simply treat the disease symptoms or non-specifically suppress the whole immune system.

Its patented, leading edge, high speed discovery platform enables it to identify and design innovative peptide-based therapies and diagnostics and it has an impressive pipeline of products in development.

Apitope has a highly experienced management team, with a proven track record in discovering and developing innovative therapeutics. Its lead product for treating multiple sclerosis is in Phase I development and is partnered with Merck Serono, a division of Merck KGaA, Darmstadt, Germany.

For more information, please go to www.apitope.com



Read at BioSpace.com

Apitope
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES